Core Viewpoint - The completion of the Phase III clinical trial for Anaprazole Sodium Enteric-Coated Tablets (brand name: Anjiewei®) by the subsidiary Xuan Zhu Bio marks a significant milestone in the treatment of adult reflux esophagitis in China, with 500 participants successfully enrolled in the study [1] Group 1: Clinical Trial Details - The Phase III clinical trial is a multi-center, randomized, double-blind, and positive drug parallel-controlled study [1] - The primary clinical endpoint is the healing rate of reflux esophagitis in participants compared to a positive control drug after an 8-week treatment period [1] - Secondary endpoints include the healing rate at week 4, severity and frequency of primary symptoms (heartburn and reflux) compared to baseline at weeks 4 and 8, and various efficacy indicators [1] Group 2: Safety Assessment - Safety indicators focus on the types, incidence, and severity of adverse events occurring during the trial [1]
四环医药(00460.HK)：安奈拉唑钠肠溶片(安久卫)治疗反流性食管炎中国III期临床试验完成全部受试者入组